Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 2/20 | 0.32 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6208972 | 0.88 | DRD3 (0.46) | GAAMAPTKDM4EDRD2DRD3 | |
| SCHEMBL6212074 | 0.75 | DRD3 (0.46) | DRD2DRD3HTR2A | |
| SCHEMBL6209400 | 0.70 | DRD3 (0.55) | CHRNA7MAPTDRD2DRD3HTR2A | |
| SCHEMBL6208852 | 0.68 | DRD3 (0.48) | GAAMAPTKDM4ESMN1; SMN2DRD2 | |
| SCHEMBL6210789 | 0.66 | DRD3 (0.55) | MAPTSMN1; SMN2DRD2DRD3HTR2A | |
| SCHEMBL7489956 | 0.62 | KDM1A (0.30) | KDM1A | |
| SCHEMBL18741400 | 0.60 | CHRNA7 (0.62) | CHRNA7GAARAD52MAPTKDM4E | |
| SCHEMBL578273 | 0.59 | GAA (0.67) | CHRNA7GAARAD52MAPTKDM4E | |
| SCHEMBL10819408 | 0.58 | KCNH2 (0.71) | CHRNA7GAARAD52MAPTKDM4E | |
| SCHEMBL30563617 | 0.58 | KCNH2 (0.71) | CHRNA7GAARAD52MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307463-B1 | PYRROLO 2,1-B]-[1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-26 | — | — | EP | disclosed |
| US-6710041-B2 | Pyrrolo[2,1-B][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-03-23 | — | — | US | disclosed |
| US-20030186959-A1 | Pyrrolo[2,1-b][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2003-10-02 | — | — | US | disclosed |
| EP-1307463-A1 | PYRROLO 2,1-B]-[1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2003-05-07 | — | — | EP | disclosed |
| WO-2002010175-A1 | PYRROLO[2,1-b][1,3]BENZOTHIAZEPINES AND THEIR USE FOR THE PREPARATION OF MEDICAMENTS WITH ANTIPSYCHOTIC ACTIVITY | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2002-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186959-A1 | Pyrrolo[2,1-b][3,1] benzothiazepines and their use for the preparation of medicaments with antipsychotic activity | TPH1, GRIN2C, GRIN2B | CHRNA7 498/4885GAA 1473/4885RAD52 4809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.